Trial Profile
A Single-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Multiple-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-709478 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Feb 2020
Price :
$35
*
At a glance
- Drugs Apinocaltamide (Primary) ; Midazolam
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 28 Jan 2020 Results to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of ACT-709478 published in the CNS Drugs
- 02 Jan 2019 Status changed from recruiting to completed.
- 01 Nov 2018 Planned End Date changed from 30 Sep 2018 to 14 Nov 2018.